Australia's most trusted
source of pharma news
Tuesday, 03 March 2026
Posted 2 March 2026 PM
Lilly has bolstered its quest to become the first pharma to bring an oral GLP-1 to Australia, sharing the full results of a landmark trial in which it trumped rival Novo Nordisk, with the TGA.
The ACHIEVE-3 study compared Lilly’s orforglipron (12mg or 36mg) with oral semaglutide (7mg or 14mg) head-to-head in adults whose type 2 diabetes was inadequately controlled with metformin.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.